Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Als Therapy Development Institute is engaged in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is assigned to 1 distinct examiner, indicating a focused interaction with the USPTO. The prosecution is localized within 1 distinct art unit, which reflects the specialized nature of the institute's current patenting efforts in the biotechnology sector and suggests a narrow range of prior art may be relevant.
Mercy Hellen Sabila is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. Given that there is 1 pending office action in total, this examiner manages the institute's entire active docket. The prosecution path for the institute is currently defined by the review and feedback provided by this specific examiner within their art unit. Success for this application will require a thorough understanding of the examiner's technical perspective and the specific procedural standards maintained by the assigned art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18303346 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SABILA, MERCY HELLEN | 60d overdue |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18303346 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SABILA, MERCY HELLEN | 1654 | §103§112DP | Non-Final OA | 60d overdue | Pending | Apr 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial